Laurus Labs to host Q1 FY27 earnings call on July 24

1 min read Updated on 11 Jul 2026, 01:37 AM

Reviewed by

Anirudha BScanX News Team

AI Summary

Laurus Labs Limited announced it will hold a conference call on July 24, 2026, at 5:00 PM IST to discuss its financial results for Q1 FY27. Hosted by DAM Capital Advisors, the call will feature a presentation on quarterly performance followed by a Q&A session. Dial-in details are available for participants across India, Singapore, Hong Kong, the USA, and the UK.

*this image is generated using AI for illustrative purposes only.

Laurus Labs Limited will organize a conference call to discuss its financial results for the first quarter of FY27 on July 24, 2026, at 5:00 PM IST. The session will be hosted by DAM Capital Advisors and will include a presentation of the quarterly performance followed by an interactive question-and-answer segment.

Conference Details

The earnings call provides stakeholders with an opportunity to review the company's operational and financial performance for Q1 FY27. Participants can join the discussion via various dial-in numbers provided for different regions.

Parameter	Details
Date and Time	Friday, July 24, 2026 - 5:00 PM IST
Primary Number	+91 22 6280 1384
Secondary Number	+91 22 7115 8285
Singapore	+8001012045
Hong Kong	+800964448
USA	+18667462133
UK	+08081011573

Company Overview

Laurus Labs is a research and development-driven pharmaceutical and biotech company. It develops and manufactures Active Pharmaceutical Ingredients (APIs) and intermediates, holding a global leadership position in therapeutic areas such as Anti-retroviral, Oncology, Cardiovascular, and Gastro. The company serves as a Contract Development and Manufacturing Organization (CDMO) for global innovators.

The company operates 15 facilities approved by global regulators including the USFDA, WHO, and EMA. During FY2026, Laurus Labs generated ₹6,813 crore in annual revenue.

Historical Stock Returns for Laurus Labs

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.10%	+2.80%	+8.12%	+57.54%	+94.67%	+147.18%

What strategic initiatives is Laurus Labs pursuing to drive growth in Q1 FY27?

How might recent regulatory changes impact the company's API and CDMO segments?

What are the expected market reactions to the upcoming financial results?

Read Next Article

Laurus Labs independent director tenure concludes on July 6, 2026

0 min read Updated on 07 Jul 2026, 02:26 AM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

AI Summary

Mrs. Aruna Bhinge's tenure as Independent Director at Laurus Labs concluded on July 6, 2026, following the completion of her second term. The company had previously intimated the exchanges on April 30, 2026, regarding the necessary details under the SEBI Master Circular.

*this image is generated using AI for illustrative purposes only.

The tenure of Mrs. Aruna Bhinge as an Independent Director of laurus labs concluded on July 6, 2026, following the completion of her second term with the pharmaceutical company. The departure took effect at the close of business hours on the specified date, as confirmed in a regulatory filing addressed to the stock exchanges.

Laurus Labs had initially informed the exchanges about the impending conclusion of her tenure through an intimation dated April 30, 2026. The company confirmed that all necessary details required under SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 were submitted in the prior communication.

The filing was submitted by G. Venkateswar Reddy, the Company Secretary & Compliance Officer of Laurus Labs Limited. The document was digitally signed on July 6, 2026, at 19:44:22 IST.